

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cutia Therapeutics

科笛集团

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2487)

CHANGE OF EXECUTIVE DIRECTOR

RESIGNATION OF EXECUTIVE DIRECTOR

The Board of Directors (the “**Board**”) of Cutia Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Huang Yuqing (“**Mr. Huang**”) has resigned as an executive director of the Company (the “**Director**”) and the chief financial officer with effect from 30 September 2026 to focus more on his other personal commitments.

The Group’s overall strategic planning, investment and financing, mergers and acquisitions, capital markets, and investor relations-related matters will henceforth be overseen by Mr. Wu Jiaru (“**Mr. Wu**”), senior vice president of the Integrated Management Department of the Group. The handover of duties between Mr. Huang and Mr. Wu has been completed smoothly, and such handover has not resulted in any material adverse impact on the business and operations of the Group.

Mr. Huang has confirmed that he has no disagreement with the Board in any respect and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to thank Mr. Huang for his contributions to the Company during his tenure.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is further pleased to announce that Dr. Lei Lei (“**Dr. Lei**”) has been appointed as an executive Director with effect from 30 September 2026.

The biographical details of Dr. Lei are set out below:

Dr. Lei Lei (雷磊), aged 41, joined the Group on 10 January 2020, and has been serving as the president of the research and development department of the Group since January 2025. Dr. Lei is primarily responsible for the overall research and development work of the Group, and leads the research and development team in carrying out a series of drug research and development projects for the treatment of dermatological diseases, which include four Class 1 new drugs (two small molecule new drugs and two biological new drugs).

During his tenure with the Group, Dr. Lei established the unique CATAME® dermatological drug technology platform, and was granted funding from the special fund for biomedicine science and technology support under the “Science and Technology Innovation Action Plan” in Shanghai. In addition, Dr. Lei has also been awarded honors such as “High-level Innovation and Entrepreneurship Talent” and “Taihu Talent” of Jiangsu Province. Dr. Lei published articles in the “Pharmaceutical Technology” journal in 2023 and 2022, respectively, on the IVPT-Stat statistical tool developed by him, which is now widely used by international peers; and published an article in the “Pharmaceutical Technology” journal in 2020 on the CuDAL-Excel statistical package developed by him, to facilitate global pharmaceutical companies in pharmaceutical process validation data evaluation and statistical batch release evaluation.

Dr. Lei has over 10 years of experiences in the development of medical/pharmaceutical products. Prior to joining the Group, Dr. Lei served as a senior product development engineer responsible for development of medical products in 3M Medical Devices and Materials Manufacturing (Shanghai) Co., Ltd (明尼蘇達礦業製造醫用器材(上海)有限公司) from October 2012 to January 2017. From January 2017 to January 2020, he worked as a senior scientist and the principal scientist in Shanghai Johnson & Johnson Pharmaceuticals Ltd. (上海強生製藥有限公司), responsible for the research and development of new products in Asia Pacific countries.

Dr. Lei obtained a bachelor’s degree in Pharmaceutical Engineering and master’s degree in Biochemistry and Molecular Biology from Southwest Jiaotong University (西南交通大學) in China in July 2006 and December 2008, respectively. He also obtained a doctor’s degree in Pharmaceutical Science from Shanghai Jiao Tong University (上海交通大學) in China in January 2013. He has been a member of the Youth Committee of the Shanghai Pharmaceutical Society Pharmaceutics Special Committee (上海市藥學會藥劑學專業委員會青年委員會) since December 2024.

As at the date of this announcement, Dr. Lei held 2,174,136 shares of the Company (each a “**Share**”), 870,220 outstanding share options and 105,644 outstanding share awards.

The Company has entered into a service contract with Dr. Lei for a term of three years commencing from 30 September 2026, subject to retirement by rotation and re-election at the next annual general meeting of the Company pursuant to the articles of association of the Company. Such service contract may be terminated by not less than 30 days’ notice in writing served by either the executive Director or the Company. Dr. Lei has agreed to serve as an executive Director with no director’s fee, but is entitled to receive, for serving as the president of the Research and Development Department, annual salaries, allowances and benefits in kind of RMB1,638,317, annual pension scheme contributions of RMB72,444 and an annual performance-related bonus, the amount of which will be determined at the discretion of the remuneration committee and the Board of the Company taking into account the operating results of the Group and his performance.

Save as disclosed above, to the best knowledge and belief of the Board having made all reasonable enquiries and confirmed by Dr. Lei, as of the date of this announcement, Dr. Lei: (i) does not have, and is not deemed to have any interest in any Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong); (ii) does not hold any other positions in the Company or any of its subsidiaries; (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder (as defined under the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company; (iv) has not held any directorships in other public companies which are listed on any securities market in Hong Kong or overseas during the last three years; and (v) does not hold any other major appointments or professional qualifications.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Dr. Lei as an executive Director that need to be brought to the attention of the Shareholders or the Stock Exchange, nor is there any other information that shall be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to welcome Dr. Lei to the Board.

By order of the Board
Cutia Therapeutics
Zhang Lele
Chief Executive Officer and Executive Director

Hong Kong, 30 September 2026

As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Dr. Lei Lei as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Mr. Lu Minfang and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Zhang Zhisong and Mr. Ye Xiaoxiang as independent non-executive directors.